OptiNose, Inc.
NASDAQ:OPTN
9.6 (USD) • At close May 21, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | OptiNose, Inc. |
| Symbool | OPTN |
| Munteenheid | USD |
| Prijs | 9.6 |
| Beurswaarde | 97,223,040 |
| Dividendpercentage | 0% |
| 52-weken bereik | 4.815 - 20.025 |
| Industrie | Drug Manufacturers—Specialty & Generic |
| Sector | Healthcare |
| CEO | Dr. Ramy A. Mahmoud M.D., M.P.H. |
| Website | https://www.optinose.com |
An error occurred while fetching data.
Over OptiNose, Inc.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)






